AI Article Synopsis
- - A case study is presented involving a 40-year-old Japanese man with Hodgkin's lymphoma who experienced an increase in blood triglyceride (TG) levels while undergoing the ABVD treatment regimen.
- - On day 58 of treatment, his fasting blood TG levels shot up to 1,451 mg/dL, which is considered significantly high.
- - No adverse symptoms were observed, but the patient was treated with pemafibrate and advised that blood TG levels should be closely monitored during ABVD therapy for those at risk of elevation.
Article Abstract
There are no reports of blood triglyceride (TG) levels increasing with the ABVD regimen. Herein, we present a case of Hodgkin's lymphoma that exhibited ABVD-induced blood TG increase. The patient was a 40-year-old Japanese man. Empiric therapy was initiated using the ABVD regimen for Hodgkin lymphoma. On day 58, the fasting blood TG concentration increased to 1,451 mg/dL. Since no adverse events were noted, 0.2 mg/day of pemafibrate was administered, and the ABVD regimen was continued. Blood TG levels should be periodically monitored during ABVD administration for the patients who are at high risk of increased blood TG levels.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023944 | PMC |
| http://dx.doi.org/10.1016/j.lrr.2023.100365 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!